Salute e Benessere

Anti-CD38 mAb Market to Accelerate Substantially During the Study Period…

Key Takeaways from the Anti-CD38 mAb Market Report Key Takeaways from the Anti-CD38 mAb Market Report Discover which therapies are expected to grab the anti-CD38 mAb market share @Anti-CD38 mAb Market Report Anti-CD38 mAb Market Dynamics The market for anti-CD38 mAbs has undergone significant growth and transformation in recent years, driven primarily by theincreasing prevalence of multiple myelomaand the d emand for more effective treatment options. The market...
PR Newswire
23/10/2024

/DISREGARD RELEASE: Osteotec/

PR Newswire
23/10/2024

Jazz Pharmaceuticals to Report 2024 Third Quarter Financial Results on November…

Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations...
PR Newswire
23/10/2024

Piramal Pharma Limited Announces Results for Q2 and H1 FY25

Key Highlights for Q2FY25 Nandini Piramal, Chairperson, Piramal Pharma Limitedsaid, "We continue our momentum of delivering healthy revenue growth accompanied by YoY EBITDA margin expansion. This has been primarily driven by consistent growth in our CDMO business which has witnessed a good pick-up in innovation related work and on-patent commercial revenues. To sustain this growth momentum and to capitalize on rising demand for sterile fill-finish capabilities, we have announced...
PR Newswire
23/10/2024

Saudi Surgeon Honored for Performing the World's First Fully Robotic Heart…

"Robotic Heart Surgery" at KFSHRC…A Leading and Accelerating Journey of Success RIYADH, Saudi Arabia, Oct.23, 2024(GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) continues to set itself apart by providing innovative specialized healthcare services, particularly through its robotic heart surgery program which has experienced accelerated success since its establishment in 2019. In its first year, the program performed 105 robotic heart surgeries…
Nasdaq GlobeNewswire
23/10/2024

Residential Bathroom Pods Market Size to Grow USD 1816.8 Million by 2030 at a…

The Global Residential Bathroom Pods Market was valued at USD 1081 Million in 2023 and is anticipated to reach USD 1816.8 Million by 2030, witnessing a CAGR of 8.3% during the forecast period 2024-2030. The Global Residential Bathroom Pods Market was valued atUSD 1081 Millionin 2023 and is anticipated to reachUSD 1816.8 Millionby 2030, witnessing a CAGR of 8.3% during the forecast period 2024-2030. Get Free Sample: ...
PR Newswire
23/10/2024

Sterilization Equipment Market to be Worth $26.77 Billion by 2031--Exclusive…

Sterilization equipment is a crucial component in the healthcare industry for preventing the spread of infectious diseases. These diseases are caused by pathogenic microorganisms, including bacteria, viruses, parasites, and fungi. They can be transmitted directly or indirectly—from person to person, through the use of infected or non-sterilized medical devices, or within contaminated healthcare environments. To mitigate the incidence of infectious diseases, healthcare facilities are increasingly…
PR Newswire
23/10/2024

KFSHRC Performs World First Robotic Left Liver Lobe Transplant

Novel Technique Hopes to Extend Robotic Transplant to More Patients RIYADH, Saudi Arabia, Oct.23, 2024(GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSHRC) has achieved another world first by performing a fully robotic left lobe liver transplant from a living donor. The novel technique led by Prof. Dieter Broering, the Executive Director of the Organ Transplant Center of Excellence, promises all the benefits of robotic transplant - increased precision,...
Nasdaq GlobeNewswire
23/10/2024

Bi-Metal Band Saw Blade Market Size to Grow USD 1939.3 Million by 2939 at a CAR…

Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-35Q11964/Global_Bi_Metal_Band_Saw_Blade_Market Get Free Sample:https://reports.valuates.com/request/sample/QYRE-Auto-35Q11964/Global_Bi_Metal_Band_Saw_Blade_Market Major Factors Driving the Growth of Bi-Metal Sand Saw Blade Market: The Bi-Metal Band Saw Blade Market is set to continue growing as industries worldwide demand more efficient and durable cutting tools. The rise in industrial manufacturing, metal...
PR Newswire
23/10/2024

Major shareholder announcement

Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and share capital through financial instruments.Per October 22, 2024, BlackRock, Inc. has adjusted its holding of shares to an equivalent of 23,548,644 shares, corresponding to 5.02% (previously 4.92%) of the total share capital attached to shares. The combined total of share...
Nasdaq GlobeNewswire
23/10/2024

OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat…

OK-101 is the first drug candidate to enroll patients specifically diagnosed with Neuropathic Corneal Pain (NCP) in a clinical trialThe Phase 2 trial is designed as a randomized, placebo-controlled, double-masked study to treat 48 NCP patientsOK-101 is the first IND granted by FDA to treat patients with NCP LONDON and NEW YORK, Oct.23, 2024(GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101...
Nasdaq GlobeNewswire
23/10/2024

KFSHRC's Patient Flow & Capacity Command Centre: a Model of Smart Healthcare…

Predicting Healthcare Demand RIYADH, Saudi Arabia, Oct.23, 2024(GLOBE NEWSWIRE) -- World-class medical institutions are striving to find sustainable health innovations to maintain top healthcare services, address operational challenges, and manage potential crises. The Patient Flow & Capacity Command Centre at King Faisal Specialist Hospital & Research Centre (KFSHRC) serves as a leading model in enabling AI-driven healthcare management. Through Big Data analysis, these...
Nasdaq GlobeNewswire
23/10/2024

World's first aptamer-based histochemistry staining kit for HPV launched by…

This aptamer-based solution offers both better performance and lower cost alternative to similar antibody-based products. Constructed from oligonucleotides, aptamers are well-known to be more stable and consistent than animal-derived antibodies. They are also less temperature-sensitive and hence easier to transport, handle and store at normal room temperature. This aptamer-based solution offers both better performance and lower cost alternative to similar antibody-based products. Constructed...
PR Newswire
23/10/2024

General Silicones Debuts Compo-SiL® for Membrane Keypads in Europe

To book a meeting with General Silicones experts at either MEDICA or Electronica, please contact: [email protected] To book a meeting with General Silicones experts at either MEDICA or Electronica, please contact: [email protected] Trade show information: MEDICA: Düsseldorf,Germany Nov. 11-14, 2024 Hall 16, Booth: E14-5 Electronica: Munich, Germany Nov. 12-15, 2024 Hall A2, Booth: 456-3 "As devices flourish and diversify, membrane keypads are becoming a...
PR Newswire
23/10/2024

Smart Immune Announces Recommended SMART101 Dose for Adult Cancer…

ReSET-02 dose escalation Phase I is completedPhase II PoC randomized segment is startingNo dose-limiting toxicities, no safety or tolerability issuesThe highest dose is to be used in both hematological and solid tumorsParis, France – October 23, 2024– Smart Immune, a clinical-stage biotechnology company pioneering ProTcell, a thymus-empowered T-cell progenitor therapy platform, today announced that the recommended dose for its lead candidate, SMART101, has been established...
Nasdaq GlobeNewswire
23/10/2024

Ipsen delivers strong sales momentum in the first nine months of 2024 and…

PARIS, FRANCE, 23 October 2024- Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its performance for the year to date and the third quarter of 2024. YTD 2024YTD 2023% changeQ32024Q32023% change€m€mActualCER 1 €m€mActualCER 1 Oncology1 829,81 744,14,9%5,8%604,0574,5 ...
Nasdaq GlobeNewswire
23/10/2024

[Ad hoc announcement pursuant to Art. 53 LR] Roche's strong sales growth of 9%…

Group salesgrew by 6% 1at constant exchange rates (CER) (2% in CHF) in the first nine months, driven by the high demand for both our medicines and diagnostics; excluding COVID-19-related products, sales increased by 8%In the third quarter, Group sales rose by 9% (6% in CHF), as they did in the second quarterPharmaceuticals Divisionsales rose by 7% in the first nine months; the strong growth of 9% in thebase business2was driven by continued high demand for our newer...
Nasdaq GlobeNewswire
23/10/2024

Press release: SEQUANA MEDICAL ANNOUNCES ADDITIONAL CONVERTIBLE FINANCING OF UP…

SEQUANA MEDICAL ANNOUNCES ADDITIONAL CONVERTIBLE FINANCING OF UP TO EUR 1.0 MILLION FROM EXISTING INVESTORSGhent, Belgium, 23 October 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that it obtained additional unsecured subordinated convertible bridge loans for a principal amount of EUR 0.5 million, with an additional tranche of…
Nasdaq GlobeNewswire
23/10/2024

TraceLink's New Singapore Office Fuels Expansion and Operational Excellence in…

The opening of the new Singapore office not only serves as a testament to TraceLink's success but also underscores its dedication to providing unparalleled support and services. The new office will serve as a center for TraceLink's operations in the region, enabling closer collaboration with customers and partners. The location, in the heart of Singapore's business district, positions the company to continue growing its talented team in an area that is central to its long-term strategy. The...
PR Newswire
23/10/2024

H&M Foundation: Global Change Award 2025 launched - with a mission to accelerate…

GCA is now seeking innovative ideas addressing different high emission areas across the textile industry value chain, including sustainable materials and processes, responsible production, mindful consumption, and 'wildcards' that support the GCA purpose. Today, only a fraction of philanthropic capital is directed to climate. "The textile industry needs all hands-on deck if we are going to meet our climate goals by 2050, and we must ensure this transition is fair for everyone...
PR Newswire
23/10/2024

JAK Inhibitors Clinical Trial Pipeline Experiences Momentum: DelveInsight…

Key Takeaways from the JAK Inhibitors Pipeline Report Key Takeaways from the JAK Inhibitors Pipeline Report Request a sample and discover the recent advances in JAK inhibitors drugs @ JAK Inhibitors Pipeline Report The JAK inhibitors pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage JAK inhibitors drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment...
PR Newswire
22/10/2024

DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the…

DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe DBV to pursue an Accelerated Approval pathway for toddlers ages 1 – 3 years-old BLA submission under Accelerated Approval is subject to completion of a six-month supplemental safety study in toddlers to be initiated in Q2 2025VITESSE Phase 3 study evaluating the Viaskin Peanut patch in children ages 4 – 7 years-old exceeded enrollment goals; Topline results on track for 4Q...
Nasdaq GlobeNewswire
22/10/2024

Nyxoah to Release Third Quarter 2024 Financial Results on November 6, 2024

Nyxoah to Release Third Quarter 2024 Financial Results on November 6, 2024Mont-Saint-Guibert, Belgium – October 22, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the third quarter 2024 on Wednesday, November 6, 2024, after...
Nasdaq GlobeNewswire
22/10/2024

Sky Medical Technology Ltd Welcomes Publication of Compelling Evidence…

Key findings from the study, published in the International Wound Journal (IWJ), demonstrate that the geko device significantly enhances treatment outcomes by stimulating the common peroneal nerve, which increases venous, arterial, and microvascular blood flow. This physiological benefit translates into a remarkable 68% increase in wound healing compared to SoC alone. Key findings from the study, published in the International Wound Journal (IWJ), demonstrate that the geko device…
PR Newswire
22/10/2024
Altri  Comunicati